Literature DB >> 17952411

Acute high-dose glycine attenuates mismatch negativity (MMN) in healthy human controls.

Sumie Leung1, Rodney J Croft, Barry V O'Neill, Pradeep J Nathan.   

Abstract

RATIONALE: Schizophrenia is commonly associated with impairments in pre-attentive change detection as represented by reduced mismatch negativity (MMN). The neurochemical basis of MMN has been linked to N-methyl-D: -aspartate (NMDA) receptor function. Glycine augments NMDA receptor function via stimulation of the glycine modulatory site of the NMDA receptor and has been shown to effectively reduce negative symptoms in schizophrenia. However, no study has investigated the possible effects of high-dose glycine on MMN. Further, the physiological consequences of administering high-dose glycine in subjects with normal NMDA receptor function are unknown.
OBJECTIVES: The aim of the present project was to investigate the acute effects of a single large dose of glycine on the human MMN in healthy subjects.
MATERIALS AND METHODS: Sixteen healthy male subjects participated in a double blind, placebo-controlled, crossover design in which each subject was tested under two acute treatment conditions separated by a 1-week washout period; placebo and 0.8 g/kg glycine. The subjects were exposed to a duration-MMN paradigm with 50-ms standard tones (91%) and 100-ms deviant tones (9%).
RESULTS: The results showed that glycine significantly attenuated duration MMN amplitude at frontal electrodes. There was no effect of glycine on MMN latencies or on amplitudes or latencies of N1, N2 and P3a.
CONCLUSIONS: These findings suggest that an acute high dosage of glycine attenuates MMN in healthy controls, raising the possibility that optimal effects of glycine and other glycine agonists may depend on the integrity of the NMDA receptor system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17952411     DOI: 10.1007/s00213-007-0976-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  71 in total

1.  Duration and frequency mismatch negativity in schizophrenia.

Authors:  P T Michie; T W Budd; J Todd; D Rock; H Wichmann; J Box; A V Jablensky
Journal:  Clin Neurophysiol       Date:  2000-06       Impact factor: 3.708

2.  Towards optimal recording and analysis of the mismatch negativity.

Authors:  J Sinkkonen; M Tervaniemi
Journal:  Audiol Neurootol       Date:  2000 May-Aug       Impact factor: 1.854

3.  Stability of the mismatch negativity under different stimulus and attention conditions.

Authors:  N Kathmann; T Frodl-Bauch; U Hegerl
Journal:  Clin Neurophysiol       Date:  1999-02       Impact factor: 3.708

4.  Glutamate receptors in the postmortem striatum of schizophrenic, suicide, and control brains.

Authors:  J T Noga; T M Hyde; M M Herman; C F Spurney; L B Bigelow; D R Weinberger; J E Kleinman
Journal:  Synapse       Date:  1997-11       Impact factor: 2.562

5.  Cerebral metabolic effects of intravenous glycine in healthy human subjects.

Authors:  Alexander Neumeister; Richard Carson; Shannan Henry; Beata Planeta-Wilson; Brendon Binneman; R Paul Maguire; David A Luckenbaugh; Cyril D'Souza; John H Krystal; J James Frost
Journal:  J Clin Psychopharmacol       Date:  2006-12       Impact factor: 3.153

6.  Dissociation of the mismatch negativity and processing negativity attentional waveforms with nitrous oxide.

Authors:  E W Pang; B Fowler
Journal:  Psychophysiology       Date:  1999-09       Impact factor: 4.016

7.  Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study.

Authors:  R B Rosse; S K Theut; M Banay-Schwartz; M Leighton; E Scarcella; C G Cohen; S I Deutsch
Journal:  Clin Neuropharmacol       Date:  1989-10       Impact factor: 1.592

Review 8.  Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis.

Authors:  Harri J Tuominen; Jari Tiihonen; Kristian Wahlbeck
Journal:  Schizophr Res       Date:  2005-01-01       Impact factor: 4.939

9.  Substantial shared genetic influences on schizophrenia and event-related potentials.

Authors:  Mei-Hua Hall; Frühling Rijsdijk; Marco Picchioni; Katja Schulze; Ulrich Ettinger; Timothea Toulopoulou; Elvira Bramon; Robin M Murray; Pak Sham
Journal:  Am J Psychiatry       Date:  2007-05       Impact factor: 18.112

Review 10.  Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review.

Authors:  James M Stone; Paul D Morrison; Lyn S Pilowsky
Journal:  J Psychopharmacol       Date:  2007-01-26       Impact factor: 4.153

View more
  13 in total

1.  Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.

Authors:  Surendra P Singh; Vidhi Singh
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

Review 2.  How human electrophysiology informs psychopharmacology: from bottom-up driven processing to top-down control.

Authors:  J Leon Kenemans; Seppo Kähkönen
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

3.  Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence.

Authors:  Deepak Cyril D'Souza; Nagendra Singh; Jacqueline Elander; Michelle Carbuto; Brian Pittman; Joanna Udo de Haes; Magnus Sjogren; Pierre Peeters; Mohini Ranganathan; Jacques Schipper
Journal:  Neuropsychopharmacology       Date:  2011-11-23       Impact factor: 7.853

Review 4.  Glycine, a simple physiological compound protecting by yet puzzling mechanism(s) against ischaemia-reperfusion injury: current knowledge.

Authors:  Frank Petrat; Kerstin Boengler; Rainer Schulz; Herbert de Groot
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

5.  Does coffee enriched with chlorogenic acids improve mood and cognition after acute administration in healthy elderly? A pilot study.

Authors:  Vanessa Cropley; Rodney Croft; Beata Silber; Chris Neale; Andrew Scholey; Con Stough; Jeroen Schmitt
Journal:  Psychopharmacology (Berl)       Date:  2011-07-20       Impact factor: 4.530

6.  Acute dopamine and/or serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants.

Authors:  Sumie Leung; Rodney J Croft; Valérie Guille; Kirsty Scholes; Barry V O'Neill; K Luan Phan; Pradeep J Nathan
Journal:  Psychopharmacology (Berl)       Date:  2009-12-10       Impact factor: 4.530

7.  Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate.

Authors:  Stephan Bickel; Daniel C Javitt
Journal:  Behav Brain Res       Date:  2009-05-09       Impact factor: 3.332

8.  Toxicity of flavor enhancers to the oriental fruit fly, Bactrocera dorsalis (Hendel) (Diptera: Tephritidae).

Authors:  Chunyan Zheng; Dongyu Yang; Zhiqiang Li; Yijuan Xu
Journal:  Ecotoxicology       Date:  2018-04-11       Impact factor: 2.823

9.  The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice.

Authors:  Philipp Singer; Joram Feldon; Benjamin K Yee
Journal:  Psychopharmacology (Berl)       Date:  2008-08-29       Impact factor: 4.530

10.  Glycine attenuates myocardial ischemia-reperfusion injury by inhibiting myocardial apoptosis in rats.

Authors:  Xiaozheng Zhong; Xiaoyu Li; Lingling Qian; Yiming Xu; Yan Lu; Jing Zhang; Nan Li; Xudong Zhu; Jingjing Ben; Qing Yang; Qi Chen
Journal:  J Biomed Res       Date:  2012-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.